2026 · Journal of clinical pharmacology · open access
Volumetric Absorptive Microsampling During Spaceflight for Analysis of Acetaminophen Pharmacokinetics in Whole Blood
Mampre et al.
The finding, in our words
In four crew members, capillary volumetric absorptive microsampling caught altered acetaminophen pharmacokinetics in flight: Cmax rose to 43,300 ng/mL from 9,110 before flight and clearance fell to 3,890 mL/h from 16,200, pointing to toxicity risk at standard dosing; four people only, but a case for microsampling where no clinic can reach.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
In 55 patients, four approaches to convert dried capillary blood concentrations to plasma equivalents were evaluated. All methods except haematocrit-based conversion yielded acceptable analytical and clinical agreement for paracetamol and metabolites, supporting the reliability of capillary microsampling for decentralised therapeutic drug monitoring.
When patiromer is taken three hours after tacrolimus, it does not alter tacrolimus exposure in kidney transplant recipients. The study also shows that self-collected capillary blood samples using volumetric absorptive microsampling (VAMS) can reliably measure tacrolimus concentrations, which simplifies pharmacokinetic studies and enables decentralised therapeutic drug monitoring.
Two feasibility studies assessed low-volume blood sampling for therapeutic drug monitoring. In patients receiving an anti-A therapeutic, drug levels were measured from finger-prick whole blood collected with Neoteryx Mitra and from capillary plasma collected with TASSO OnDemand, and compared with venipuncture samples. The work outlines practical considerations for adopting these patient-centric microsampling methods in decentralised trials and clinical care.
In ten healthy volunteers, radiprodil pharmacokinetics measured by Aqua-Cap™ Drummond microsampling closely matched conventional venous blood draws, whereas Mitra™ microsampling gave marginally lower exposure values. Both microsampling methods fell within the accepted bioequivalence range, indicating they could enable patient-centric therapeutic drug monitoring and future paediatric decentralised trials.
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.